Business Wire05.26.20
Endologix Inc., a developer and marketer of treatments for aortic disorders, has appointed Jane E. Kiernan to its board of directors. Kiernan has also been appointed to serve on the Audit Committee and the Nominating, Governance and Compliance Committee.
“We are thrilled to add an executive of Jane’s caliber to our board,” commented Dan Lemaitre, Endologix board chairman. “I’m confident that Jane’s extensive industry experience will be a key asset as we continue to pursue our long-term growth strategy.”
“Jane’s 30 years of financial and operational expertise in the healthcare sector will be instrumental as we take Endologix to the next stage of growth,” said John Onopchenko, CEO of Endologix Inc. “The strategic insight Jane has gained through a wealth of executive and board experience will be invaluable for Endologix as we continue to drive innovation in the abdominal aortic aneurysms (AAA) market.”
Kiernan has served on the board of directors of Axonics Modulation Technologies Inc. since 2019 and currently serves on its audit committee. In 2017, she co-founded K2 Biotechnology Ventures, an investment firm engaged in developing and commercializing portfolios of university and medical center innovations in partnership with venture capital, healthcare corporations, and philanthropic healthcare foundation partners. She previously served on the board of directors of American Medical Systems from 2006 through 2011, when it was acquired by Endo Pharmaceuticals.
During her distinguished career, Kiernan served as CEO and board member of Salter Labs from 2010 to 2017, over which time she and the team developed and executed a strategy to double the size of the company. Prior to joining Salter Labs, she spent nine years at Baxter Healthcare Corporation in executive and general management roles of increasing responsibility, eventually responsible for a $1.5 billion global parenteral nutrition and IV fluid therapy business. Prior to Baxter, Kiernan served as vice president of Finance, Distribution and Services at Allegiance Healthcare Corporation, where she co-led the successful turnaround of a $4 billion distribution business.
“I am very excited to be joining Endologix at such a pivotal time in the company’s history,” commented Kiernan. “I look forward to working closely with the members of the Endologix board and leadership team as we revitalize the business and seek opportunities to drive stockholder value through innovation and improved patient outcomes.”
Kiernan earned her bachelor's degree in business administration from Southern Methodist University in Dallas, Texas.
“We are thrilled to add an executive of Jane’s caliber to our board,” commented Dan Lemaitre, Endologix board chairman. “I’m confident that Jane’s extensive industry experience will be a key asset as we continue to pursue our long-term growth strategy.”
“Jane’s 30 years of financial and operational expertise in the healthcare sector will be instrumental as we take Endologix to the next stage of growth,” said John Onopchenko, CEO of Endologix Inc. “The strategic insight Jane has gained through a wealth of executive and board experience will be invaluable for Endologix as we continue to drive innovation in the abdominal aortic aneurysms (AAA) market.”
Kiernan has served on the board of directors of Axonics Modulation Technologies Inc. since 2019 and currently serves on its audit committee. In 2017, she co-founded K2 Biotechnology Ventures, an investment firm engaged in developing and commercializing portfolios of university and medical center innovations in partnership with venture capital, healthcare corporations, and philanthropic healthcare foundation partners. She previously served on the board of directors of American Medical Systems from 2006 through 2011, when it was acquired by Endo Pharmaceuticals.
During her distinguished career, Kiernan served as CEO and board member of Salter Labs from 2010 to 2017, over which time she and the team developed and executed a strategy to double the size of the company. Prior to joining Salter Labs, she spent nine years at Baxter Healthcare Corporation in executive and general management roles of increasing responsibility, eventually responsible for a $1.5 billion global parenteral nutrition and IV fluid therapy business. Prior to Baxter, Kiernan served as vice president of Finance, Distribution and Services at Allegiance Healthcare Corporation, where she co-led the successful turnaround of a $4 billion distribution business.
“I am very excited to be joining Endologix at such a pivotal time in the company’s history,” commented Kiernan. “I look forward to working closely with the members of the Endologix board and leadership team as we revitalize the business and seek opportunities to drive stockholder value through innovation and improved patient outcomes.”
Kiernan earned her bachelor's degree in business administration from Southern Methodist University in Dallas, Texas.